COVID-19 Evidence Reviews
as of 10/21/20
menu
 
 

WHO Evidence Collaborative Reviews
 
= living review
= draft/preprint   |  
= meets mimimum quality standards   |  

A review with this mark was peer-reviewed, described systematic search and study selection, and included critical appraisal of primary studies.
latest update
date
report
select
9/18/20
WHO REACT Working Group | JAMA
Aim: To estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality.
WHO COLLABORATIVE
CANDIDATE THERAPEUTICS
9/14/20
Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. | Cochrane Database of Systematic Reviews
Aim: To assess the effects of quarantine (alone or in combination with other measures) of individuals who had contact with confirmed cases of COVID19, who travelled from countries with a declared outbreak, or who live in regions with high transmission of the disease.
UPDATED
WHO COLLABORATIVE
INFECTION CONTROL
6/17/20
Agarwal A, Basmaji J, Muttalib F, et al. | Can J Anaesth
Aim: To describe the efficacy and safety of HFNC in acute hypoxemic respiratory failure; and to determine the risk of dispersion, aerosol generation and associated transmission of COVID-19 with HFNC.
UPDATED
WHO COLLABORATIVE
5/18/20
Mackey K, King VJ, Gurley S, et al. | VA Evidence Synthesis Program
Aim: To synthesize evidence on the role of ACE inhibitor and ARB use on patient outcomes in COVID-19 as well as evidence on the benefits and harms of initiating these medications to treat patients with COVID-19.
UPDATED
WHO COLLABORATIVE
VA ESP
5/14/20
Yaacoub S, Schunemann H, Khabasa J, et al. | BMJ Global Health
Aim: To systematically review the literature to scope and assess the effects of specific strategies for the management of the bodies.
UPDATED
WHO COLLABORATIVE
5/6/20
Chou R, Dana T, Buckley D, et al. | Ann Intern Med
Aim: To examine the burden of SARS-CoV-2, SARS-CoV-1, and Middle Eastern respiratory syndrome (MERS)-CoV on HCWs and risk factors for infection, using rapid and living review methods.
WHO COLLABORATIVE
4/30/20
 | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
4/27/20
Halpin D, Singh D, Hadfield RM | Eur Respir J
Aim: To evaluate whether pre-morbid use or continued administration of inhaled steroids is a risk factor for adverse outcomes in acute respiratory infections due to COVID-19, SARS or MERS. 
WHO COLLABORATIVE
CANDIDATE THERAPEUTICS
4/19/20
 | WHO
Aim: To assess the effects of prior and current use of NSAIDs in patients with acute viral respiratory infections on acute severe adverse events , on acute health care utilization, as well as on quality of life and long-term survival.
WHO COLLABORATIVE
4/16/20
Ford N, Vitoria M, Rangaraj A, et al. | J Int AIDS Soc
Aim: To systematically review the clinical outcomes of using antiretroviral drugs for the prevention and treatment of coronaviruses and planned clinical trials.
WHO COLLABORATIVE
CANDIDATE THERAPEUTICS
4/15/20
What is the efficacy and acceptability of universal mask use by health care workers in health care settings in preventing respiratory infection during epidemics? 
Chou R, Dana T | Pacific Northwest Evidence-Based Practice Center
Aim: To inform evidence based guidance on universal mask use by HCWs in health care settings during the COVID-19 pandemic.
WHO COLLABORATIVE
4/6/20
Devane D | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
4/6/20
Vandvik PO | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
4/6/20
Chou R | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
4/6/20
Reveiz L | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
4/6/20
Reveiz L | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
4/6/20
Reveiz L | Cochrane COVID Rapid Reviews
WHO COLLABORATIVE
4/6/20
Reveiz L | PAHO
WHO COLLABORATIVE
4/5/20
Physical distance from a known COVID-19 patient and droplet transmission; with and without mask use 
Akl E, Schunemann H | American University of Beirut Medical Center (protocol under development)
WHO COLLABORATIVE
4/4/20
Corticosteroids in patients with COVID-19, SARS, MERS, influenza, community acquired pneumonia, or ARDS 
Ye Z, Guyatt G | McMaster University (protocol under development)
WHO COLLABORATIVE
4/2/20
Ash for hand hygiene 
Soares-Weiser K | Cochrane (protocol under development)
WHO COLLABORATIVE
4/1/20
 | Centre for Health Communication and Participation
WHO COLLABORATIVE
3/28/20
Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19 and other viral respiratory infections: Rapid Review   
von Philipsborn P, Biallas R, Burns J, et al. | Ludwig Maximilian University
Aim: To assess the effects of prior and current use of NSAIDs in patients with acute viral respiratory infections on acute severe adverse events , on acute healthcare utilization, as well as on quality of life and long-term survival.
WHO COLLABORATIVE
3/26/20
Quarantine: Individual and community for influenza 
Gartlehner G | Danube University (protocol under development)
WHO COLLABORATIVE
3/25/20
 | Centre for Health Communication and Participation
WHO COLLABORATIVE
Noninvasive ventilation as an aerosol generating procedures  
Schunemann H | McMaster University
WHO COLLABORATIVE